2024-02-01
1. Executive Summary of the Month
As we step into the New Year, the biotechnology industry in China continues to evolve, marked by strategic collaborations and a surge in licensing and cooperation agreements.
In January 2024, China biotechnology industry has been particularly active in out-licensing, with a substantial count of 17 deals. These global partnerships not only showcase China’s willingness to leverage global expertise but also position the nation as a key player in the global biotech industry, contributing to cross-border innovation and knowledge exchange.
The Chinese Biotech sector has also actively pursued in-licensing agreements, with 5 deals suggesting an openness to integrating external innovations into the industry’s portfolio. This strategic flexibility demonstrates China’s commitment to acquiring novel technologies or products from global sources, enhancing its capabilities and catalyzing domestic growth.
Conversely, China Biotech Industry has forged 6 domestic licensing and cooperation deals, emphasizing a commitment to strengthening local partnerships, fostering innovation, and promoting the exchange of scientific knowledge within the country’s borders. The Global Biotech Industry has demonstrated a total of 58 deals, indicating a strong and proactive engagement in International Collaborations.
随着新年的到来，中国生物医药行业继续快速发展，战略合作以及资产许可和合作交易激增成为显著特征。
2024年1月，中国对外授权交易尤其活跃，达成了17项协议。这些跨境合作不仅展示了中国融入全球创新网络的意愿，同时也彰显了中国作为全球生物医药行业重要参与者的地位，为跨境创新和知识交流做出了贡献。
中国生物医药行业也在积极寻求资产引进，达成的5项交易表明了中国企业将外部创新成果纳入自身发展蓝图的开放态度。这种战略灵活性体现了中国致力于从全球获取新技术或产品的承诺，从而提升自身能力并催化国内增长。
与此同时，中国生物医药行业达成了6项国内资产许可和合作协议，体现了加强本地合作、培育创新以及促进国内科学知识交流的重要性。全球生物医药行业则达成了58项协议，积极主动参与国际合作已成为共识。
2. Licensing Deals
2a. Out-Licensing Deals
2b. In-Licensing Deals
2c. Domestic Licensing Deals
3. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
添加小药通助理，申请进入药通中国活动及路演群
BioToChina.org 